NCT06201507 is a Phase 2 clinical trial of Brentuximab vedotin in Hodgkin Lymphoma, sponsored by Beijing Children's Hospital.

Who is sponsoring NCT06201507?

NCT06201507 is sponsored by Beijing Children's Hospital.

What drugs are being tested in NCT06201507?

Interventions in NCT06201507: Brentuximab vedotin, Rituximab, Doxorubicin, Vincristine, Dacarbazine.

What condition does NCT06201507 study?

NCT06201507 studies Hodgkin Lymphoma.

Is NCT06201507 still recruiting?

NCT06201507 is currently status unknown. Last updated 12 January 2024.

Last reviewed 2024-01-12 · How we verify

NCT06201507

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BV-AVD-R Treatment Children Hodgkin's Lymphoma

Status unknown Phase 2 Last updated 12 January 2024

What this trial tests

Phase 2 trial testing Brentuximab vedotin in Hodgkin Lymphoma in 44 participants. Status unknown.

Timeline

1 October 2022

Primary endpoint
31 December 2024

31 December 2025

Quick facts

Lead sponsor	Beijing Children's Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	44
Start date	1 October 2022
Primary completion	31 December 2024
Estimated completion	31 December 2025
Sites	1 location across China

Drugs / interventions tested

Brentuximab vedotin
Rituximab — full drug profile →
Doxorubicin
Vincristine (vincristine) — full drug profile →
Dacarbazine (dacarbazine) — full drug profile →

Conditions studied

Hodgkin Lymphoma — all drugs for Hodgkin Lymphoma →

Sponsor

Beijing Children's Hospital

Who can join

Under 18, any sex, with Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to use modified Brentuximab Vedotin+doxorubicin+vinblastine+dacarbazine+Rituximab(BV-AVD-R) regimen in Chinese Classical Hodgkin's Lymphoma(HL) children. The main questions it aims to answer are: * \[Overall Response Rate(ORR) :Complete Response(CR)+Partial Response(PR)\] * \[progression-free survival (PFS), event-free survival (EFS) and overall survival (OS) at 6 months and 1 year.\] Participants will be given modified BV-AVD-R regimen according to rapid early responders (RER) or slow early responders (SER) after 2 cycles.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pathobiological Features and Therapeutic Opportunities Linked to TNF Family Member Expression in Classic Hodgkin Lymphoma.
Alibrahim MN, Gloghini A, Carbone A. · · 2024 · cited 4× · PMID 39682256 · DOI 10.3390/cancers16234070

Verify or expand the search:

Other trials of Brentuximab vedotin

Trials testing the same drug.

NCT05149768 — Open Label Extension Study of Brentuximab Vedotin in Early dcSSc · Phase 2 · recruiting
NCT05922904 — PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lym · Phase 2 · active not recruiting
NCT05313243 — Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma · Phase 2 · recruiting
NCT05414500 — Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides · Phase 1 · recruiting
NCT05442554 — A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma · Phase 4 · completed

Other recruiting trials for Hodgkin Lymphoma

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT06176690 — Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas · Phase 1 · recruiting
NCT07002216 — BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma · Phase 2 · recruiting

Other Beijing Children's Hospital trials

Trials by the same sponsor.

NCT07412119 — Research on Disease Control and Mental Health Status of Adolescent Asthma Patients · not yet recruiting
NCT06837584 — Control and Treatment of Outpatient Children With Asthma · not yet recruiting
NCT07199101 — Multicenter Pediatric Low-Dose CT Protocol: Development and Clinical Verification · NA · not yet recruiting
NCT07488728 — Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-A · NA · recruiting
NCT07029958 — Improved Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Protocol for the Treatment of Epstein Barr Vir · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06201507 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Children's Hospital
Last refreshed: 12 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06201507.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing